Trisalus Life Sciences, Inc.
Clinical trials sponsored by Trisalus Life Sciences, Inc., explained in plain language.
A medical device company focused on interventional oncology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Liver-Directed drug combo shows promise for rare eye cancer
Disease control Stopped earlyThis study tested a new drug called SD-101, given directly into the liver through a special pressure-enabled infusion, alone or with standard immunotherapy drugs. It was for adults with a rare eye cancer (uveal melanoma) that had spread mainly to the liver. The main goals were to…
Phase 1 • Sponsor: TriSalus Life Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Liver cancer drug combo study halted early
Disease control Stopped earlyThis study tested a new way to deliver an immune-boosting drug (SD-101) directly into the liver along with standard immunotherapy for people with advanced liver cancer. It included 23 adults whose cancer had not responded to prior treatment. The goal was to find a safe dose and s…
Phase 1/2 • Sponsor: TriSalus Life Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC